Drug target · DRD2
D2
Dopamine D2 receptor
11 compounds in the CNS pipeline act on D2.
Compounds targeting D2
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| BrexpiprazoleprimarySmall molecule | Partial agonist | Ki 0.3 nM | Filed (NDA)Post-traumatic stress disorder | Otsuka Pharmaceutical Co., Ltd. |
| Olanzapine extended-release injectable suspension (TEV-'749)primarySmall molecule | Antagonist | — | Filed (NDA)Schizophrenia | Teva Pharmaceutical Industries Ltd. |
| Brilaroxazine (RP5063)primarySmall molecule | Partial agonist | Ki 0.37 nM | Phase 3Schizophrenia | Reviva Pharmaceuticals Holdings, Inc. |
| LB-102 (N-methylamisulpride)primarySmall molecule | Antagonist | Ki 0.8 nM | Phase 3Schizophrenia | LB Pharmaceuticals Inc. |
| LYBALVI (olanzapine/samidorphan)primarySmall molecule | Antagonist | Ki 11 nM | Phase 3Schizophrenia | Alkermes plc |
| ENX-104primarySmall molecule | Antagonist | — | Phase 1Major depressive disorder | Engrail Therapeutics, Inc. |
| Lumateperone (ITI-007)Small molecule | Antagonist | Ki 32 nM | ApprovedSchizophrenia | Intra-Cellular Therapies, Inc. |
| Iloperidone LAISmall molecule | Antagonist | Ki 6.3 nM | Phase 3Schizophrenia | Vanda Pharmaceuticals Inc. |
| Milsaperidone (VHX-896)Small molecule | Antagonist | Ki 15.8 nM | Phase 3Major depressive disorder | Vanda Pharmaceuticals Inc. |
| ALTO-207Small molecule | Agonist | — | Phase 2Treatment-resistant depression | Alto Neuroscience, Inc. |
| ITI-1284 (deulumateperone)Small molecule | Antagonist | — | Phase 2Alzheimer's disease | Intra-Cellular Therapies, Inc. |